Investigational Device Exemption (IDE) enables Imbed’s Silver-Gallium, Ultra-Thin Matrix Technology to be tested in human clinical studies, a key step towards marketing approval Fully synthetic ...
--(BUSINESS WIRE)--Imbed Biosciences (“Imbed”), a pioneer in breakthrough wound care synthetic matrix technology, today announced the U.S. Food and Drug Administration (FDA) has approved an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback